Machine Learning

Sana Biotech’s new data shows it can edit stem cells directly in the body, a potential game-changer for blood disorders and a challenge to current therapies.

PHOTRON's takeover of AOS Technologies signals a major shift in the high-speed camera market, with deep implications for automotive safety and defense.

As the humanoid robotics market soars towards $7.7B, one firm is recruiting top talent to find the next big winner. What does this move signal to investors?

As the aging U.S. grid strains under explosive demand, industrial leaders are turning to microgrids for energy independence and financial stability.

John Crowley, who fought to save his own children, will now shape the future of medicine as he headlines the landmark 2026 MDA conference.

A new clinical trial in Malaysia could democratize advanced cancer care, testing an affordable, donor-derived immunotherapy challenging costly personalized treatments.

FBI data shows most active threats begin outdoors. New tech is extending security beyond the building, creating an integrated, automated defense.

Vyome's positive Phase 2 data targets a silent suffering in cancer care. This analysis explores its strategy to dominate a potential $1 billion market.

SAB Biotherapeutics' novel T1D therapy shows promise with a unique safety profile, challenging the status quo and offering new hope for patients.

Newron launches a pivotal US trial for its novel schizophrenia drug, evenamide, aiming to help millions who don't respond to current treatments.

New data reveals Syndax's Revuforj is a game-changer for leukemia, sparking a battle for market dominance in targeted cancer therapy.

The new SANY-Pony.ai autonomous truck is production-ready for 2026, promising to slash freight costs, boost profits, and redefine logistics.

A breakthrough drug for a rare brain cancer sweeps prestigious international awards, offering patients a new, targeted therapy to delay aggressive treatments.

After two decades under its visionary founder, Oxford Nanopore taps a commercial scaling expert to lead its next chapter of global growth and market dominance.

New data shows Ascentage Pharma's drug achieves responses where a leading therapy fails, signaling a strategic coup in the high-stakes oncology market.

A medical breakthrough dismantles a core barrier in cancer treatment, making stem cell transplants a reality for nearly everyone, regardless of ancestry.

A 209kg opium seizure reveals how Canada's billion-dollar investment in AI and intelligence is disrupting sophisticated global drug smuggling networks.

A Canadian firm's breakthrough promises to produce renewable natural gas at price parity with fossil fuels. Is this the key to unlocking a greener economy?

Boston-based 1910 Genetics unveils an AI model that bypasses decades-old barriers, opening a vast new frontier for treating Alzheimer's and Parkinson's.

Plume Network launches institutional-grade asset vaults on Solana, connecting giants like WisdomTree to high-speed DeFi and forging a new era of real-world yield.